Brief Report
VARIAR Study: Assessment of Short-term Efficacy and Safety of Rituximab Compared to an Tumor Necrosis Factor Alpha Antagonists as Second-line Drug Therapy in Patients With Rheumatoid Arthritis Refractory to a First Tumor Necrosis Factor Alpha Antagonist
Estudio VARIAR: VAloración de la eficacia y seguridad a corto plazo en artritis reumatoide del uso de RItuximab comparado con Antagonistas del factor de necrosis tumoral alfa en segunda línea terapéutica en pacientes con artritis reumatoide Refractarios a un primer antagonista del factor de necrosis tumoral alfa
Vicenç Torrente-Segarraa,
, Asunción Acosta Pereirab, Rosa Morlac, José Miguel Ruizd, Teresa Clavaguerae, Ramon Figulsa, Hector Corominasa, Carme Gelib, Rosa Rosellóf, Juan José de Agustíng, Cayetano Alegreg, Carolina Pérezh, Angel Garcíai, Arturo Rodríguez de la Sernab
Corresponding author
a Hospital General Hospitalet-Moisès Broggi, Sant Joan Despí, Barcelona, Spain
b Hospital Santa Creu i Sant Pau, Barcelona, Spain
c Hospital del Vendrell, El Vendrell, Tarragona, Spain
d Hospital de Viladecans, Viladecans, Barcelona, Spain
e Hospital de Palamós, Palamós, Girona, Spain
f Hospital de San Jorge, Huesca, Spain
g Hospital de la Vall d’Hebron, Barcelona, Spain
h Hospital de Mollet, Mollet del Vallès, Barcelona, Spain
i Hospital de Torrevieja, Torrevieja, Alicante, Spain
Ver másRead
6131
Timeswas read the article
2294
Total PDF
3837
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 4 | 22 | 26 |
| 2025 5 | 130 | 70 | 200 |
| 2025 4 | 93 | 29 | 122 |
| 2025 3 | 105 | 26 | 131 |
| 2025 2 | 104 | 26 | 130 |
| 2025 1 | 90 | 42 | 132 |
| 2024 12 | 91 | 23 | 114 |
| 2024 11 | 84 | 54 | 138 |
| 2024 10 | 71 | 38 | 109 |
| 2024 9 | 67 | 14 | 81 |
| 2024 8 | 80 | 34 | 114 |
| 2024 7 | 52 | 29 | 81 |
| 2024 6 | 54 | 24 | 78 |
| 2024 5 | 47 | 25 | 72 |
| 2024 4 | 40 | 23 | 63 |
| 2024 3 | 35 | 18 | 53 |
| 2024 2 | 30 | 16 | 46 |
| 2024 1 | 28 | 15 | 43 |
| 2023 12 | 32 | 28 | 60 |
| 2023 11 | 41 | 14 | 55 |
| 2023 10 | 45 | 33 | 78 |
| 2023 9 | 86 | 40 | 126 |
| 2023 8 | 31 | 12 | 43 |
| 2023 7 | 32 | 24 | 56 |
| 2023 6 | 36 | 24 | 60 |
| 2023 5 | 55 | 22 | 77 |
| 2023 4 | 37 | 11 | 48 |
| 2023 3 | 80 | 30 | 110 |
| 2023 2 | 70 | 31 | 101 |
| 2023 1 | 30 | 13 | 43 |
| 2022 12 | 81 | 43 | 124 |
| 2022 11 | 52 | 23 | 75 |
| 2022 10 | 76 | 30 | 106 |
| 2022 9 | 24 | 38 | 62 |
| 2022 8 | 33 | 35 | 68 |
| 2022 7 | 35 | 34 | 69 |
| 2022 6 | 44 | 29 | 73 |
| 2022 5 | 44 | 41 | 85 |
| 2022 4 | 43 | 38 | 81 |
| 2022 3 | 45 | 32 | 77 |
| 2022 2 | 22 | 20 | 42 |
| 2022 1 | 33 | 36 | 69 |
| 2021 12 | 34 | 44 | 78 |
| 2021 11 | 42 | 33 | 75 |
| 2021 10 | 70 | 58 | 128 |
| 2021 9 | 42 | 53 | 95 |
| 2021 8 | 39 | 35 | 74 |
| 2021 7 | 22 | 67 | 89 |
| 2021 6 | 47 | 28 | 75 |
| 2021 5 | 43 | 44 | 87 |
| 2021 4 | 79 | 97 | 176 |
| 2021 3 | 38 | 24 | 62 |
| 2021 2 | 33 | 25 | 58 |
| 2021 1 | 27 | 27 | 54 |
| 2020 12 | 39 | 24 | 63 |
| 2020 11 | 33 | 15 | 48 |
| 2020 10 | 23 | 24 | 47 |
| 2020 9 | 38 | 27 | 65 |
| 2020 8 | 26 | 20 | 46 |
| 2020 7 | 18 | 30 | 48 |
| 2020 6 | 37 | 19 | 56 |
| 2020 5 | 40 | 11 | 51 |
| 2020 4 | 28 | 24 | 52 |
| 2020 3 | 17 | 5 | 22 |
| 2020 2 | 1 | 0 | 1 |
| 2018 12 | 2 | 0 | 2 |
| 2018 5 | 4 | 1 | 5 |
| 2018 4 | 41 | 9 | 50 |
| 2018 3 | 118 | 12 | 130 |
| 2018 2 | 24 | 8 | 32 |
| 2018 1 | 16 | 3 | 19 |
| 2017 12 | 31 | 9 | 40 |
| 2017 11 | 27 | 10 | 37 |
| 2017 10 | 31 | 7 | 38 |
| 2017 9 | 26 | 10 | 36 |
| 2017 8 | 28 | 14 | 42 |
| 2017 7 | 41 | 20 | 61 |
| 2017 6 | 40 | 19 | 59 |
| 2017 5 | 43 | 24 | 67 |
| 2017 4 | 30 | 17 | 47 |
| 2017 3 | 32 | 41 | 73 |
| 2017 2 | 17 | 13 | 30 |
| 2017 1 | 54 | 39 | 93 |
| 2016 12 | 58 | 47 | 105 |
| 2016 11 | 41 | 43 | 84 |
| 2016 10 | 5 | 5 | 10 |
Show all
